导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -2.23% | 2875/4773 |
| 近一周 | -2.31% | 1763/5462 |
| 近一月 | -4.41% | 2448/5421 |
| 近一季 | -7.94% | 2597/5209 |
| 近半年 | -3.15% | 2136/4920 |
| 近一年 | 0.35% | 2589/4366 |
| 近两年 | 47.05% | 1573/2954 |
| 近三年 | 28.25% | 1122/2253 |
| 成立以来 | 34.15% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.80% 3422/4961 |
12.69% 2138/5312 |
- - |
- - |
| 2025 | 20.49% 2116/4813 |
-1.10% 2576/3635 |
2.26% 1709/4076 |
18.93% 2224/4524 |
0.18% 2151/4813 |
| 2024 | 17.49% 683/3463 |
2.97% 648/2808 |
-1.22% 989/3014 |
17.82% 1114/3129 |
-1.96% 1901/3463 |
| 2023 | -9.41% 1159/2656 |
4.59% 913/2280 |
-4.11% 1049/2385 |
-3.02% 829/2515 |
-6.87% 1948/2655 |
| 2022 | -20.11% 935/2207 |
-14.55% 968/1919 |
7.16% 517/2016 |
-14.30% 1065/2113 |
1.80% 1134/2208 |
| 2021 | -3.45% 905/1822 |
-3.12% 763/1255 |
4.32% 900/1330 |
-5.87% 872/1466 |
1.49% 907/1822 |
| 2020 | 30.60% 518/1250 |
-10.06% 743/1028 |
13.98% 578/1067 |
12.06% 408/1164 |
13.69% 338/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 天弘沪深300ETF VS. 长安沪深300非周期A(740101) |